Nature:DNA聚合酶θ抑制同源重组,促进肿瘤发生

2015-02-09 佚名 生物谷

近日,著名国际期刊nature在线刊登了来自美国纽约大学医学院Agnel Sfeir研究小组的一项最新研究成果,他们通过研究发现非同源末端连接过程能够利用聚合酶θ促进肿瘤细胞中的端粒发生染色体末端融合。这项研究对治疗携带同源重组修复突变基因的肿瘤具有重要意义。   研究人员指出,细胞的非同源末端连接(NHEJ)机制能够促进部分基因组重排,但同时也可能导致细胞性状发生转化。这种容错修复

近日,著名国际期刊nature在线刊登了来自美国纽约大学医学院Agnel Sfeir研究小组的一项最新研究成果,他们通过研究发现非同源末端连接过程能够利用聚合酶θ促进肿瘤细胞中的端粒发生染色体末端融合。这项研究对治疗携带同源重组修复突变基因的肿瘤具有重要意义。
 
研究人员指出,细胞的非同源末端连接(NHEJ)机制能够促进部分基因组重排,但同时也可能导致细胞性状发生转化。这种容错修复途径会在端粒发生脱保护,有害染色体末端融合的情况下被触发。通过下一代测序技术,研究人员发现通过NHEJ修复途径会产生非TTAGGG核苷酸插入到功能紊乱的端粒融合断点位置。通过对负责核苷酸随机插入的聚合酶活性进行研究,研究人员发现聚合酶θ是NHEJ途径中一个非常重要的因子。抑制编码聚合酶θ的基因polq会抑制NHEJ在功能紊乱的端粒处的修复过程,并且阻断非端粒位点的染色体易位。除此之外,在缺失polq的小鼠中,同源重组修复率增加。最后,研究人员通过实验证实删除polθ能够降低BRCA基因缺失的肿瘤细胞的存活。
 
综上所述,该文章发现聚合酶θ在非同源末端连接途径中发挥重要作用,它能够促进染色体通过端粒断点融合导致细胞性状改变。这一研究结果表明抑制具有诱变作用的聚合酶可能成为治疗携带同源重组修复突变基因的肿瘤的一种有效途径。

原始出处

Mateos-Gomez PA1, Gong F2, Nair N3, Miller KM2, Lazzerini-Denchi E3, Sfeir A1.Mammalian polymerase θ promotes alternative NHEJ and suppresses recombination.Nature. 2015 Feb 2.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880495, encodeId=d7d91880495c6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 14 04:05:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041872, encodeId=f76920418e2fc, content=<a href='/topic/show?id=d289389808b' target=_blank style='color:#2F92EE;'>#同源重组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38980, encryptionId=d289389808b, topicName=同源重组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 10 08:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955977, encodeId=e01719559e7c1, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Mar 08 15:05:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15855, encodeId=6b981585598, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-10-14 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880495, encodeId=d7d91880495c6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 14 04:05:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041872, encodeId=f76920418e2fc, content=<a href='/topic/show?id=d289389808b' target=_blank style='color:#2F92EE;'>#同源重组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38980, encryptionId=d289389808b, topicName=同源重组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 10 08:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955977, encodeId=e01719559e7c1, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Mar 08 15:05:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15855, encodeId=6b981585598, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880495, encodeId=d7d91880495c6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 14 04:05:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041872, encodeId=f76920418e2fc, content=<a href='/topic/show?id=d289389808b' target=_blank style='color:#2F92EE;'>#同源重组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38980, encryptionId=d289389808b, topicName=同源重组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 10 08:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955977, encodeId=e01719559e7c1, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Mar 08 15:05:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15855, encodeId=6b981585598, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-03-08 晓辰
  4. [GetPortalCommentsPageByObjectIdResponse(id=1880495, encodeId=d7d91880495c6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Wed Oct 14 04:05:00 CST 2015, time=2015-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2041872, encodeId=f76920418e2fc, content=<a href='/topic/show?id=d289389808b' target=_blank style='color:#2F92EE;'>#同源重组#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38980, encryptionId=d289389808b, topicName=同源重组)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=21015, createdName=heli0118, createdTime=Thu Dec 10 08:05:00 CST 2015, time=2015-12-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1955977, encodeId=e01719559e7c1, content=<a href='/topic/show?id=30ac80810c0' target=_blank style='color:#2F92EE;'>#聚合酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80810, encryptionId=30ac80810c0, topicName=聚合酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a5712500001, createdName=晓辰, createdTime=Sun Mar 08 15:05:00 CST 2015, time=2015-03-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=15855, encodeId=6b981585598, content=已阅, beContent=null, objectType=article, channel=null, level=null, likeNumber=110, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c68e1614119, createdName=windmilL1989, createdTime=Mon Feb 16 14:23:00 CST 2015, time=2015-02-16, status=1, ipAttribution=)]
    2015-02-16 windmilL1989

    已阅

    0

相关资讯

医生必看:高通量基因测序产前筛查与诊断技术规范(试行)

2015年1月15日,卫计委妇幼司发布第一批产前诊断试点单位,同时发布了高通量基因测序产前筛查与诊断技术规范(试行)。与卫计委医政司发布的第一批试点相比,本次妇幼司发布的《通知》更为详细。这份高通量基因测序产前筛查与诊断技术规范(试行)规定了高通量基因测序产前筛查在临床上的适用范围、临床服务流程及临床质量控制。另外,还给出了高通量基因测序产前筛查与诊断知情同意书、临床申请单及临床报告单的参考模

Nature Communications:监测肿瘤状态的特殊基因

近日,刊登在国际杂志Nature Communications上的一篇研究论文中,来自西奈山医疗中心(Mount Sinai Medical Center)的研究人员通过研究发现两种癌症药物可以开启特殊基因的表达,而这种特殊基因则可以告知肿瘤细胞使其处于休眠状态。 文章中研究者表示,当名为NR2F1的基因开启后其就会重编程肿瘤细胞使其处于休眠状态;而当该基因的表达关闭后肿瘤细胞就会开始分裂并且发

Nat Commun:新型乳腺癌基因的重大发现:BCL11A基因活跃在难治的三阴性乳腺癌中

一项新的研究确定了活跃在乳腺癌亚型中的基因。研究表明,过度活化的BCL11A基因驱动着三阴性乳腺癌发展和进程。 在人类细胞和老鼠上的研究为靶向治疗这种侵略性的肿瘤类型提供了新的途径。 有许多类型的乳腺癌对治疗的反应大有不同,也有不同的预测。大约五分之一的患者患有三阴性乳腺癌,这些癌症缺乏三种受体蛋白,而这些蛋白用于其他亚型的乳腺癌的应对激素疗法。近年来已经获得明显研究结果,大多数三阴性肿瘤有基

Nature:线粒体DNA损伤引发抗病毒固有免疫反应

近日,来自美国耶鲁大学医学院的研究人员著名国际期刊nature在线发表了他们的一项最新研究成果,他们发现在抗病毒天然免疫过程中,线粒体发挥了至关重要的作用。   在正常情况下,每个细胞内的线粒体DNA(mtDNA)有成千上万个拷贝,并且被包装成几百个高级结构,称为类核。大量mtDNA结合蛋白TFAM负责调控类核结构,数目以及相互之间的隔离。完全删除mtDNA会严重损伤氧化磷酸化过程,

Nature biotechnology:新发现染色质绝缘子或可用于人类基因治疗

                插入突变和遗传毒性通常代表造血系统肿瘤的恶化,同时也是实现基因治疗前景所面临的最大障碍。George Stamatoyannopoulos等人研究出一种能够识别作为绝缘子发挥功能的紧凑序列元件的方法,或对实现基因

Cancer cell: myc失调促进代谢重编程和肿瘤发生还需一因子

                                 &n